Treatment Strategies for Deficiency of Adenosine Deaminase 2

N Engl J Med. 2019 Apr 18;380(16):1582-1584. doi: 10.1056/NEJMc1801927.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adalimumab / therapeutic use
  • Adenosine Deaminase / deficiency*
  • Adenosine Deaminase / genetics
  • Adolescent
  • Adult
  • Antibodies, Monoclonal / therapeutic use
  • Child
  • Child, Preschool
  • Drug Therapy, Combination
  • Etanercept / therapeutic use*
  • Humans
  • Infliximab / therapeutic use
  • Intercellular Signaling Peptides and Proteins / deficiency*
  • Intercellular Signaling Peptides and Proteins / genetics
  • Metabolism, Inborn Errors / drug therapy*
  • Metabolism, Inborn Errors / therapy
  • Plasma*
  • Secondary Prevention
  • Stroke / prevention & control*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Young Adult

Substances

  • Antibodies, Monoclonal
  • Intercellular Signaling Peptides and Proteins
  • Tumor Necrosis Factor-alpha
  • golimumab
  • Infliximab
  • ADA2 protein, human
  • Adenosine Deaminase
  • Adalimumab
  • Etanercept